StemCyte Inc.

StemCyte is dedicated to expanding the applications of cell therapy to address currently incurable diseases, paving the way for a healthier future through its guiding principle: “Better Cell, Better Life.” Founded in the United States in 1997, StemCyte has established a strong presence in Taiwan and India. To date, it has built a public cord blood bank with over 36,000 units, making it the largest in scale globally, with unparalleled racial diversity and superior quality. StemCyte is also among the few biotechnology companies that operate both public and private cord blood banks. Over the past 20 years, StemCyte has provided more than 2,300 cord blood units to over 350 transplant centers worldwide, supporting the treatment of various diseases. In November 2024, StemCyte became the first private company in the world to obtain FDA approval for a cord blood biologics license. Moving forward, StemCyte will continue its commitment to advancing the development of cord blood cell therapies, ensuring that physicians and patients around the globe have access to safe and effective cell therapy resources. For more information, please visit https://stemcytebio.com/.